Details of Host Protein-DME Interaction (HOSPPI)

General Information of Drug-Metabolizing Enzyme (DME ID: DME0169)
DME Name	Serum paraoxonase/arylesterase 1 (PON1), Homo sapiens	DME Info
UniProt ID	PON1_HUMAN
EC Number	EC: 3.1.1.2 (Click to Show/Hide the Complete EC Tree) Hydrolases Ester bond hydrolase Carboxylic ester hydrolase EC: 3.1.1.2
Lineage	Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Interactome

Disease Specific Interactions between Host Protein and DME (HOSPPI)
ICD Disease Classification 02 Neoplasms
ICD-11: 2A00 Brain cancer		Click to Show/Hide the Full List of HOSPPI: 13 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Glioblastoma		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 8.34E-07; delta-beta: 3.32E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Anaplastic pilocytic astrocytoma		Moderate hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Moderate hypermethylation p-value: 1.61E-08; delta-beta: 2.82E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the PON1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Malignant astrocytoma		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 8.78E-28; delta-beta: 3.09E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Brain neuroepithelial tumour		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 1.40E-14; delta-beta: 3.23E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Oligodendroglial tumour		Moderate hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Moderate hypermethylation p-value: 4.20E-02; delta-beta: 2.88E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the PON1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Multilayered rosettes embryonal tumour		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 1.38E-13; delta-beta: 3.94E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Myxopapillary ependymoma		Moderate hypomethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Moderate hypomethylation p-value: 4.46E-04; delta-beta: -2.49E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the PON1 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		RELA YAP fusion ependymoma		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 8.68E-24; delta-beta: 3.12E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Diffuse midline glioma		Moderate hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Moderate hypermethylation p-value: 6.72E-14; delta-beta: 2.21E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the PON1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Oligodendroglioma		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 4.18E-20; delta-beta: 3.89E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Atypical teratoid/rhabdoid tumour		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 4.30E-11; delta-beta: 3.40E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Anaplastic pleomorphic xanthoastrocytoma		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 1.56E-07; delta-beta: 3.95E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
DNA methyltransferase (DNMT)		Peripheral neuroectodermal tumour		Moderate hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Moderate hypermethylation p-value: 4.73E-03; delta-beta: 2.51E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the PON1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
ICD-11: 2B30 Lymphoma		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Lymphoma		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 1.36E-10; delta-beta: 3.37E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
ICD-11: 2B5F Uterine carcinosarcoma		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Uterine carcinosarcoma		Moderate hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Moderate hypermethylation p-value: 8.55E-05; delta-beta: 2.38E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the PON1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
ICD-11: 2B90 Colorectal cancer		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Colorectal cancer		Moderate hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Adjacent Tissue	Moderate hypermethylation p-value: 4.05E-05; delta-beta: 2.52E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the PON1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue adjacent to the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data of patients in the normal section of the tissue adjacent to the disease section Download DME methylation data in the tissue of healthy individual
ICD-11: 2C12 Liver cancer		Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI
Transcription-factor regulation
Sterol element-binding 2 (SREBF2)		Liver cancer		Activation
Uniprot ID	SRBP2_HUMAN
Interaction Name	SREBF2-PON1 interaction				[1]
Studied Cell Lines	HuH7 cell line
Ensembl ID	ENSG00000198911
Description	Sterol element-binding 2 (SREBF2) is reported to activate the transcription of PON1 gene, which leads to an increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between SREBF2 and PON1 can activate the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
Transcription factor Sp1 (SP1)		Liver cancer		Activation
Uniprot ID	SP1_HUMAN
Interaction Name	SP1-PON1 interaction				[2]
Studied Cell Lines	HepG2 cell line
Ensembl ID	ENSG00000185591
Description	Transcription factor Sp1 (SP1) is reported to activate the transcription of PON1 gene, which leads to an increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between SP1 and PON1 can activate the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
ICD-11: 2C25 Lung cancer		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Lung cancer		Moderate hypomethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Other Disease Section	Moderate hypomethylation p-value: 5.35E-03; delta-beta: -2.21E-01
Description	DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the PON1 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals DME methylation in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual Download DME methylation data in the tissue of the other disease section
ICD-11: 2C30 Melanoma		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Melanoma		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 1.59E-07; delta-beta: 3.58E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
ICD-11: 2C82 Prostate cancer		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Prostate cancer		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 3.28E-06; delta-beta: 4.39E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
ICD-11: 2E06 Prostate cancer metastasis		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
DNA methylation
DNA methyltransferase (DNMT)		Prostate cancer metastasis		Significant hypermethylation
Interaction Name	DNMT-PON1 interaction
The Methylation Level of Disease Section Compare with the Healthy Individual Tissue	Significant hypermethylation p-value: 3.84E-04; delta-beta: 6.16E-01
Description	DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between DNMT and PON1 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME methylation in the diseased tissue of patients DME methylation in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Methylation Level			Click to View the Clearer Original Diagram
Download DME methylation barchart for all samples Download DME methylation data of patients in the disease section of the tissue Download DME methylation data in the tissue of healthy individual
ICD Disease Classification 08 Nervous system diseases
ICD-11: 8B11 Ischemic stroke		Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
Non-coding RNA regulation
hsa-miR-616-3p		Ischemic stroke		Suppression
miRBase ID	MIMAT0004805
Interaction Name	hsa-miR-616-3p--PON1 regulation				[3]
Studied Cell Lines	Ischemic stroke cells
Description	hsa-miR-616-3p is reported to suppress PON1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PON1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1.

References
1	Quercetin up-regulates paraoxonase 1 gene expression via sterol regulatory element binding protein 2 that translocates from the endoplasmic reticulum to the nucleus where it specifically interacts with sterol responsive element-like sequence in paraoxonase 1 promoter in HuH7 liver cells. Metabolism. 2010 Sep;59(9):1372-8.
2	Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 Cells. Atherosclerosis. 2004 Oct;176(2):279-87.
3	A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis. Atherosclerosis. 2013 May;228(1):161-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.